Company Overview and News
CEO cashed out his shares and resigned, and Moody's downgraded its rating outlook in response to Cash Flow and EBITDA guidance cut.
WFCNP SXCP MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA SXC WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO GM.WS.A WFC.PRN GM.WS.B SUN GM.WS.C WFC.PRY MS GM WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS ADNT MS.PRI MS.PRK BA GM.WSB
24 of 86 Energy Sector top yield stocks were deemed "safer" for dividends because they showed positive annual-returns, and free cash-flow yields greater than their dividend yields 6/14/18.
HEP EQM CAPL SHLX GLOP.PRA GLOP.PRB GLOP SUN GPP VLP TEP SNMP
Energy firms with over 5% dividend yield showed a refining & marketing firm tops on its list, CrossAmerica Partners, for upside and net gains, and Sanchez Midstream for yield.
SRLP USAC TLP CAPL DM DKL SUN GPP SOOCY SEP SNMP
Champion dividend stocks sustain 25 or more annual dividend increases; Contenders show 10-24; Challengers have 5-9. WallStars show >.7% price-target upsides.
ABR PM HMLP O.PRF O OPRF KMB NNN.PRD ABRN NNN.PRF NNN.PRE ABRN.CL SIR SUN ABR.PRB HMLP.PRA ABR.PRC NNN ABR.PRA
Champion dividend stocks sustain 25 or more annual dividend increases; Contenders show 10 to 24; Challengers have 5 to 9. WallStar selections all show .7% or higher price target upsides.
PM HMLP ENB SEP ABRN PBFX DKL SUN PBF ABR TLP PEGI NRZ MDP SRLP ENB TCP ABRN.CL SIR PPL PEG ABR.PRB HMLP.PRA ABR.PRC ABR.PRA
“Send somebody to the Stop 'N Go. We need some celery and a can of fake snow, a bag of lemons and some Diet Sprites, a box of tampons, some Salem Lights. Hallelujah, everybody say Cheese. Merry Christmas from the Family.” Lyrics, “Merry Christmas from the Family” by Robert Earl Keen
CST ANCUF ATD.A ANCTF KR ATD.B CST.WI SUN MUR.WI MUR
Ferrellgas Partners LP (FGP - Free Report) reported third-quarter fiscal 2018 adjusted earnings of 18 cents per unit, missing the Zacks Consensus Estimate of 26 cents by 30.8%. Total Revenues In the reported quarter, Ferrellgas Partners’ total revenues were $515.8 million, missing the Zacks Consensus Estimate of $621 million by 17%. The top line also declined 4.1% from $538 million in the prior-year quarter.
SRLP CLMT SUN FGP
27 of 74 stocks sporting 10%+yields were tagged as "safer" for dividends because they showed positive one-year returns and free-cash-flow yields greater than their dividend yields as of 6/1/18.
AIY TCRX AINV SXCP DX AIB ORC TCRD TCRZ VEDL TSLF KIROY KUMBF GMLP CAPL SUN DX.PRB DX.PRA VEDL SNMP
70 U.S. stocks displayed 10%+ forward yield, $5+ prices, and $100M+ market caps as of 6/1/18. Yields above 11.7% narrowed the list to 30 for comparison.
CCR TCRX GARS HGKGF HGKGY TCRD TCRZ VEDL TSLF CUSI KIROY PLTYF KUMBF GMLP CAPL OFS SUN VEDL SNMP
16 of 77 10%+Dividend WallStars stocks were tagged as "safer" for dividends because they showed positive one-year returns and free cash flow yields greater than their dividend yields as of.
ANH.PRA AIY AINV CPLP HMLP ANH.PRC ANH.PRB ANH ORC CIM CAPL SUN CIM.PRA TCRX DX AIB TCRD TCRZ CIM.PRB TSLF GMLP DX.PRB DX.PRA HMLP.PRA
21 of 79 Dividend Challengers (5-9 annual dividend hikes) were tagged "safer" because they showed positive annual-returns, and free cash-flow yields greater than dividend yields 5/7/18.
MPW ABR GEO PEGI HMLP GLOP.PRA WLK GLOP.PRB GLOP VLP VLO TEP SIX ABRN EQM ABRN.CL SIR SUN PEG SWM ABR.PRB HMLP.PRA ABR.PRC ABR.PRA
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to SUN / Sunoco LP on message board site Silicon Investor.
as of ET